Journal
/
Inmunología y contagio
/
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
JoVE Revista
Inmunología y contagio
Se requiere una suscripción a JoVE para ver este contenido.  Inicie sesión o comience su prueba gratuita.
JoVE Revista Inmunología y contagio
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

16,688 Views

•

10:03 min

•

August 01, 2013

DOI:

10.3791/50662-v

DOI:
10.3791/50662-v

•

10:03 min
August 01, 2013

•

4 Views
, , ,
1Department of Microbiology and Immunology,University of Rochester School of Medicine and Dentistry, 2Departments of Immunology and Microbial Sciences,The Scripps Research Institute

Explore More Videos

Recombinant ArenavirusVaccine DevelopmentFDA-approved Vero CellsArenavirus Reverse GeneticsCell-based Arenavirus Minigenome SystemsRecombinant Infectious ArenavirusesTrisegmented ArenavirusesSingle-cycle Infectious ArenavirusesReporter GenesPlasmid-based Reverse GeneticsRodent Cell LinesFDA-licensed VaccineVaccine Vectors

Read Article

Cite this Article

Cheng, B. Y., Ortiz-Riaño, E., de la Torre, J. C., Martínez-Sobrido, L. Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells. J. Vis. Exp. (78), e50662, doi:10.3791/50662 (2013).

Download .ris file

Copy

Share Video

.

Copy